-
Carter, HE, Zannino, D, Simes, RJ, Schofield, DJ, Howard, K, Zalcberg, JR, Price, TJ, Tebbutt, NC.
The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: Results from the Australasian phase III MAX study.
European Journal of Cancer
50(3)
:
535 -543
2014
view publication
-
Kashyap, R, Jackson, P, Hofman, MS, Eu, P, Beauregard, J-M, Zannino, D, Hicks, RJ.
Rapid blood clearance and lack of long-term renal toxicity of 177Lu-DOTATATE enables shortening of renoprotective amino acid infusion.
European Journal of Nuclear Medicine and Molecular Imaging
40(12)
:
1853 -1860
2013
view publication
-
Marlton, P, Seymour, JF, Bradstock, K, Lewis, ID, Saal, R, McMillen, L, Di Iulio, J, Zannino, D, Grigg, A.
High Dose Cytarabine (HiDAC) and Fludarabine Without Anthracycline For Patients With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): The Australasian Leukaemia and Lymphoma Group (ALLG) AMLM13 Study.
Blood
122(21)
:
1444
2013
view publication
-
Dickinson, M, Herbert, K, Sardjono, C, Le, T, Link, E, Zannino, D, Ruell, S, Seymour, JF, Kenealy, M, Prince, HM.
P-276 High doses of eltrombopag are well-tolerated in conjunction with azacitidine and demonstrate encouraging activity in patients with MDS and AML.
Leukemia Research
37:
s147
2013
view publication
-
Kenealy, M, Seymour, JF, Benson, W, Stevenson, W, Eek, R, Zantomio, D, Cunningham, I, Hiwase, D, Cowan, L, Zannino, D.
P-272 The combination of azacitidine and lenalidomide is deliverable without unexpected toxicity; interim safety results of the ALLG MDS4 randomised trial.
Leukemia Research
37:
s145
2013
view publication